HPV Associated Disorders Market Growth & Trends
The global HPV associated disorders market size is expected to reach USD 24.7 billion by 2030, registering a CAGR of 4.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by an increase in disease prevalence and emergence of targeted therapies.
Most cancers associated with HPV have high mortality rates. For instance, cervical cancer has a mortality rate of over 50%. Cervical Intraepithelial Neoplasia (CIN) and Anal Intraepithelial Neoplasia (AIN) could advance into cervical and anal cancer, respectively, in the absence of timely treatment. However, these cancers generally have a slow progression rate, providing possibilities for prevention and treatment.
The prevalence of HPV infection-especially in young women-has increased in the recent decades and continues to increase. Globally, cervical cancer stands as the fourth most prevalent cancer in women. Since HPV is a major causative factor for this, the increasing disease prevalence is a key driving force for market growth.
It is estimated that more than 430 million women in India-15 years or above-are considered at risk for developing HPV associated disorders. The annual incidence of these diseases among Indian women is over 122,900 and disease mortality is around 68,000. In the ancillary market of cervical cancer, India records the highest age-standardized disease incidence in South Asia at 22, followed by Bangladesh at 19.2, Sri Lanka at 13, and Iran at 2.8.
Proactive government initiatives and rise in consumer awareness are likely to drive growth. The CDC initiated National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in 1991. The program was created to promote & and facilitate low-cost or free screening for women. Along similar lines, the Indian government recently started an operational framework for mandatory screening for cervical, breast, and oral cancer in people aged 30 years or more. The initiative marked the first nationwide oncological screening program.
Request a free sample copy or view report summary: HPV Associated Disorders Market Report
HPV Associated Disorders Market Report Highlights
Cervical cancer led the market with a share of 34.7% in 2023, fueled by increased awareness of HPV’s role in the disease and government initiatives for vaccination and screening.
Vaccines dominated the market with a revenue share of 63.5% in 2023. Vaccines have demonstrated high efficacy in preventing HPV infections and cancers.
Retail pharmacies are projected to grow at the fastest CAGR of 5.1% over the forecast period. Retail pharmacies offer patients convenience and accessibility through a comprehensive range of HPV-related products, including vaccines and treatments.
Asia Pacific HPV associated disorders market is expected to register the fastest CAGR of 5.9% in the forecast period. Market growth in the region is propelled by rapid economic growth and improved healthcare infrastructure.
HPV Associated Disorders Market Segmentation
Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region:
HPV Associated Disorders Type Outlook (Revenue, USD Million, 2018 - 2030)
Cervical Intraepithelial Neoplasia (CIN)
Cervical Cancer
Anal Intraepithelial Neoplasia (AIN)
Anal Cancer
Genital Warts
Others
HPV Associated Disorders Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Vaccines
Anti-viral Drugs
Others
HPV Associated Disorders Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Others
HPV Associated Disorders Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in HPV Associated Disorders Market
Merck & Co., Inc.
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd
Pfizer Inc.
AstraZeneca
Biocon
Lilly
AbbVie Inc.
